Literature case analysis of drug-induced liver injury induced by GLP-1 receptor agonists
- VernacularTitle:GLP-1受体激动剂致药物性肝损伤的文献病例分析
- Author:
Menghua ZHANG
1
;
Ying ZHU
1
;
Ziyang WU
1
;
Yanhua WANG
2
;
Xiangzun XIONG
3
;
Liyan MIAO
1
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Soochow University，Jiangsu Suzhou 215006，China
2. Dept. of Pharmacy，the Second Affiliated Hospital of Kunming Medical University，Kunming 650101，China
3. Dept. of Pharmacy，Chongqing University Central Hospital （Chongqing Emergency Medical Center），Chongqing 400010，China
- Publication Type:Journal Article
- Keywords:
GLP-1 receptor agonists;
drug-induced liver
- From:
China Pharmacy
2025;36(20):2561-2565
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the clinical characteristics of drug-induced liver injury （DILI） induced by glucagon- like peptide-1 receptor agonists （GLP-1RAs）， and to provide a reference for safe clinical medication. METHODS Using search terms such as “GLP-1”“GLP-1RAs”“semaglutide” “drug-induced liver injury”， relevant studies from PubMed， Embase， the Cochrane Library， CNKI， Wanfang Data and VIP were retrieved. Descriptive analysis was performed on cases of DILI induced by GLP-1RAs. RESULTS A total of 11 studies， comprising 11 patients， were included. Among them， 4 were male （36.4%） and 7 were female （63.6%）. Patient ages ranged from 17 to 64 years； 5 patients （45.5%） were between 50 and 65 years old. Six patients were treated for diabetes， and five for weight loss. Ten patients had underlying diseases. The shortest time to the onset of DILI was 5 days after medication， while the longest was approximately 180 days. The DILIs induced by GLP-1RAs were mainly hepatocellular injury type （6 cases）； severity levels included severe （3 cases）， moderate （6 cases）， and mild （2 cases）. Gastrointestinal symptoms and jaundice were the most common clinical manifestations. The association between DILI and GLP- 1RAs was assessed as “probable” in 10 cases and “possible” in 1 case. All 11 patients improved after drug discontinuation and （or） corresponding treatment. CONCLUSIONS DILI induced by GLP-1RAs is relatively concentrated in patients aged 50-65， with a higher incidence in females. The risk may be further increased in patients with underlying diseases. Clinical use of these agents should enhance pharmaceutical care， including identification of high-risk populations and patient education （especially symptom recognition）. When relevant symptoms appear， the drug should be discontinued immediately， with liver-protective therapy initiated when necessary， to ensure patient safety of drug use.
